Section Arrow
Quote
BRNS.NASDAQ
- Barinthus Biotherapeutics plc
(Financial Status)
Quotes are at least 15-min delayed:2026/07/09 06:33 EDT
Pre Market
Last
 0.6899
+0.0525 (+8.24%)
Bid
0.531
Ask
0.69
High 0.6899 
Low 0.6236 
Volume 11.95K 
Regular Hours (Closed)
Last
 0.6374
+0.0085 (+1.35%)
Day High 
0.68 
Prev. Close
0.6289 
1-M High
0.7654 
Volume 
163.24K 
Bid
0.531
Ask
0.69
Day Low
0.6101 
Open
0.6156 
1-M Low
0.59 
Market Cap 
25.69M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.66 
20-SMA 0.68 
50-SMA 0.67 
52-W High 2.92 
52-W Low 0.512 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.29/-1.15
Enterprise Value
34.95M
Balance Sheet
Book Value Per Share
1.63
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.33
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TVRDTvardi Therapeutics Inc5+1.9+61.29%-- 
Pre Market 4.58 -0.42 -8.40%
RXRXRecursion Pharmaceuticals3.72-0.12-3.13%-- 
Pre Market 3.72 0 0.00%
CRNXCrinetics Pharmaceuticals83.49-0.04-0.05%-- 
Pre Market 83.5 +0.01 +0.01%
GOSSGossamer Bio0.169-0.0085-4.79%-- 
Pre Market 0.1784 +0.0094 +5.56%
SLSSELLAS Life Sciences Group13.76+0.26+1.93%-- 
Pre Market 13.7835 +0.0235 +0.17%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of itsproprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.